$MRNA (Moderna, Inc.) Support & Resistance Levels, AI Price Target & Institutional Flow.
Today, $MRNA (Moderna, Inc.) trades at $198.85 (-0.24%) with a 20/100 Momentum Pulse (STORMY) and 14D RSI at 42 (PULLBACK ZONE (42)). Unlock the live $MRNA support and resistance levels, 30D Put Wall floor, 20D SMA pivot, Call Wall ceiling, dark pool flow, and locked 1-Month AI Price Target (+14.2% upside corridor) below—or create a free 24/7 AI quant agent to guard $MRNA.
Moderna (MRNA) stock is down today due to investor concerns over potential share dilution following the pricing of an upsized $2.6 billion offering of 0.00% convertible senior notes due 2032, despite recent positive news regarding its personalized mRNA cancer vaccine and FDA approvals for updated COVID-19 vaccines.
$MRNA (Moderna, Inc.) Live Key Levels, RSI & Valuation Matrix
| $MRNA Technical Metric | Live Value | $MRNA Fundamental / Regime Metric | Live Status |
|---|---|---|---|
| Live Spot Price (24h Change) | $198.85 (-0.24%) | Market Capitalization | $77.85B |
| 30-Day Mechanical Support Floor (Put Wall) | $195.00 (1.94% cushion) | 52-Week High / Low Range | $23.55 – $280.80 |
| 20-Day Simple Moving Average (20D SMA) | $225.26 | Trailing P/E Ratio & Dividend Yield | Growth / N/A |
| 10-Day Exponential Moving Average (10D EMA) | $219.16 | Average Daily Volume (Liquidity) | 12.14M shares |
| 30-Day Resistance Ceiling (Call Wall) | $269.00 (35.28% upside to test) | Next Scheduled Earnings / Catalyst Window | 2026-11-06 |
| 14-Day Relative Strength Index (RSI) | PULLBACK ZONE (42) | Saku Momentum Pulse & Health Rating | 20/100 Momentum • 25/100 Health |
Should You Buy $MRNA Stock Now or Wait?
Moderna's positive Phase 3 results for its personalized mRNA cancer vaccine, intismeran, in melanoma patients, along with recent FDA approvals for updated COVID-19 vaccines and an analyst upgrade to 'buy' with a $180 price target, highlight strong long-term pipeline potential and future revenue streams.
The upsized $2.6 billion convertible senior notes offering raises significant concerns about future share dilution, while the company continues to report substantial losses and negative cash flow, with the average analyst price target remaining significantly below current trading levels.
$MRNA Support & Resistance, Institutional Flow & Catalysts.
$MRNA Support & Resistance
Spot Price: $198.85 | 30-Day Support Floor: $195.00 (1.94% above) | 10-Day EMA: $219.16 | 20-Day SMA Pivot: $225.26 | 30-Day Resistance Ceiling: $269.00 (35.28% below) | 14-Day RSI: 42 (PULLBACK ZONE (42)) | 30-Day Trading Corridor: 37.95% span. AI Desk Note: Immediate support for MRNA is identified in the $133-$136 zone, with further support at $127.80, while immediate resistance is around the prior close of $142.77 and the $147.55 level.
$MRNA Institutional & Whale Flow
Institutional activity indicates a net cautious flow as concerns over dilution from the upsized $2.6 billion convertible note offering appear to outweigh any positive sentiment, with 14.83% of the public float held short as of mid-August.
$MRNA Catalyst Outlook
Key upcoming events include the full Phase 3 data presentation for the INTerpath-001 melanoma vaccine, planned FDA discussions for the cancer vaccine, results from trials in other cancer types, and an Analyst Day scheduled for November 12, 2026.
Latest $MRNA (Moderna, Inc.) Breaking News & Headlines
About Moderna, Inc. ($MRNA)
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.
Saku's quantitative engine continuously monitors $MRNA's 30-day mechanical support floor ($195.00), 20-day simple moving average ($225.26), and 30-day resistance ceiling ($269.00) alongside off-exchange dark pool block prints and SEC filings.
Hatch Your Own 24/7 AI Co-Pilot to Guard $MRNA.
Step inside the 3D Quant Sanctuary and claim Workstation #4 to hatch your personal AI analyst (Momentum, Dip-Buyer, or Value & Catalyst style). Your agent monitors $MRNA 24/7 with locked 1-month price targets, hard stop-loss tripwires, 3x/day shift briefings, and live Koi Bridge debates.

What are the live 30-day support and resistance levels for $MRNA (Moderna, Inc.)?
Spot Price: $198.85 | 30-Day Support Floor: $195.00 (1.94% above) | 10-Day EMA: $219.16 | 20-Day SMA Pivot: $225.26 | 30-Day Resistance Ceiling: $269.00 (35.28% below) | 14-Day RSI: 42 (PULLBACK ZONE (42)) | 30-Day Trading Corridor: 37.95% span. AI Desk Note: Immediate support for MRNA is identified in the $133-$136 zone, with further support at $127.80, while immediate resistance is around the prior close of $142.77 and the $147.55 level. $MRNA currently registers a Saku Momentum Pulse score of 20/100 and a Fundamental Health score of 25/100.
Why is $MRNA (Moderna, Inc.) moving and what is the bull vs. bear thesis?
Bull Thesis: Moderna's positive Phase 3 results for its personalized mRNA cancer vaccine, intismeran, in melanoma patients, along with recent FDA approvals for updated COVID-19 vaccines and an analyst upgrade to 'buy' with a $180 price target, highlight strong long-term pipeline potential and future revenue streams. Bear Thesis: The upsized $2.6 billion convertible senior notes offering raises significant concerns about future share dilution, while the company continues to report substantial losses and negative cash flow, with the average analyst price target remaining significantly below current trading levels.
What are $MRNA's key fundamentals, 52-week range, and upcoming catalysts?
Moderna, Inc. ($MRNA) trades with a market cap of $77.85B, and a 52-week range of $23.55 to $280.80. Key upcoming events include the full Phase 3 data presentation for the INTerpath-001 melanoma vaccine, planned FDA discussions for the cancer vaccine, results from trials in other cancer types, and an Analyst Day scheduled for November 12, 2026.